Quantcast

Mesothelioma Advocate Participates in DoD Cancer Research Peer-Review

December 31, 2013

The Mesothelioma Applied Research Foundation (Meso Foundation) nominated Mr. Rich Mosca as the consumer reviewer with the Department of Defense’s (DoD) Peer Reviewed Cancer Research Program (PRCRP), to help Congress allocate $15 million in research funds available for several cancers, including mesothelioma.

Alexandria, VA (PRWEB) December 31, 2013

Mesothelioma cancer advocate and activist, Rich Mosca, recently participated in the evaluation of research applications submitted to the Peer Reviewed Cancer Research Program (PRCRP) sponsored by the Department of Defense. Mr. Mosca was nominated for participation in the program by the Mesothelioma Applied Research Foundation. As a consumer reviewer, he was a full voting member, along with prominent scientists, at meetings to help determine how the $15 million appropriated by Congress for Fiscal Year 2013 (FY13) will be spent on future research for eight specific cancers: blood, colorectal, kidney, and pancreatic cancer; melanoma and other skin cancers; mesothelioma, neuroblastoma, and pediatric brain tumors.

Consumer reviewers are asked to represent the collective view of individuals living with these cancers, family members, and those who may be affected in the future, when they prepare comments on the impact of the research on issues such as prevention, screening, diagnosis, treatment, and quality of life after diagnosis.

The Meso Foundation was instrumental in making mesothelioma an eligible topic within the DoD’s research programs. The first ever DoD research grant for mesothelioma was awarded in 2008 and amounted to $1.3 million. A total of $8.8 million has been awarded to mesothelioma research through the Peer Reviewed Medical Research Program and the Peer Reviewed Cancer Research Program, both divisions of the Congressionally Directed Medical Research Program, which is administered by the Department of Defense.

To date, the Meso Foundation has nominated four consumer reviewers who have served as voting members on the DoD panels.

Colonel Wanda L. Salzer, M.D., Director of the Congressionally Directed Medical Research Programs, expressed her appreciation for the perspectives of the consumer advocates in the scientific review sessions. “The Consumer Reviewers on each panel are instrumental in helping the scientists understand the patient’s perspective and provide valuable insight into the potential impact of the proposed project. They bring with them a sense of urgency and remind all of the human element involved in medical research.”

Scientists applying propose to conduct innovative cancer research aimed at improving the lives of all individuals living with these cancers and their families. The PRCRP fills important gaps not addressed by other funding agencies by supporting groundbreaking, high-risk, high-gain research while encouraging out-of-the-box thinking.

More information about the Department of Defense Peer Reviewed Cancer Research Program is available on the website: http://cdmrp.army.mil.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,500 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in Navy shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION

The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by it. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish more effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.2 million to research. More information is available at http://www.curemeso.org.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11455619.htm


Source: prweb



comments powered by Disqus